Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.
MUNICH–(BUSINESS WIRE)–June 24, 2014–
SIRION Biotech GmbH, enables its customers to advance the field of gene therapy through multiple proprietary viral vector platforms. Today the company announced that its Chief Technology Officer, Christian Thirion, Ph.D. participated on a panel on Monday with leading gene therapy industry experts covering the regulatory needs in clinical development at the Piper Jaffray GenomeRx Symposium, at the Yale Club in New York City.
“It is an honor to be part of a distinguished panel as the field of gene therapy continues to deliver important advances to patients. At SIRION, we see our role in the field continuing to evolve as a critical viral vector supplier across multiple proprietary platforms,” said Christian Thirion, Ph.D., Chief Technology Officer.
About SIRION Biotech GmbH
Started in 2006, SIRION Biotech today has partnered with more than 100 clients in 300 projects across the globe. The company has raised more than $8M in venture financing from European funds since its inception. SIRION Biotech’s customers include leading academic and pharmaceutical and biotechnology companies.
U.S. Media Contact:
LaVoie Health Science
David Connolly, 617-374-8800 x108
European and Asian Contact:
SIRION Biotech GmbH
Dieter Lingelbach, +49 89 120 172 22
VentureBeat’s VB Insight team is studying marketing analytics...
Chime in here, and we’ll share the results